Inhibition of reinforcing effects of morphine and naloxone: precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists

Neuropharmacology

Volumn 37, Issue 8, 1998, Pages 1033-1042

  Popik, P ^a   Mamczarz, J ^a   Fraczek M ^a   Widla M ^a   Hesselink, M ^b   Danysz, W ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Conditioned place preference; Extinction; Microdialysis; Morphine; Naloxone precipitated morphine withdrawal; NMDA glycine antagonists

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; GLYCINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; MORPHINE ADDICTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; BINDING, COMPETITIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; QUINOLONES; RATS; RATS, WISTAR; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0031660188     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00105-1     Document Type: Article

References (39)

1. Berger, P., Farrel, K., Sharp, F., Skolnick, P., 1994. Drugs acting at the strychnine insensitive glycine receptor do not induce HSP-70 protein in the cingulate cortex. Neurosci. Lett. 168, 147-150.
2. Bespalov, A., Dumpis, M., Piotrovsky, L., Zvartau, E., 1994. Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. Eur. J. Pharmacol. 264, 233-239.
3. Bisaga, A., Gianelli, P., Popik, P., 1997. Opiate withdrawal using dextromethorphan. Am. J. Psychiatr. 154, 584.
4. Bristow, L.J., Flatman, K.L., Hutson, P.H., Kulagowski, J.J., Leeson, P.D., Young, L., Tricklebank, M.D., 1996a. The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. J. Pharmacol. Exp. Ther. 277, 578-585.
5. Bristow, L.J., Hutson, P.H., Kulagowski, J.J., Leeson, P.D., Matheson, S., Murray, F., Rathbone, D., Saywell, K.L., Thorn, L., Watt, A.P., Tricklebank, M.D., 1996b. Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex. J. Pharmacol. Exp. Ther. 279, 492-501.
6. Cappendijk, S.L., de Vries, R., Dzoljic, M.R., 1993. Excitatory amino acid receptor antagonists and naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Eur. Neuropsychopharmacol. 3, 111-116.
7. Chen, J., Graham, S., Moroni, F., Simon, R., 1993. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J. Pharmacol. Exp. Ther. 267, 937-941.
8. Chiamulera, C., Costa, S., Reggiani, A., 1990. Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology 102, 551-552.
9. Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D., Quack, G., 1994. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural. Transm. Park. Dis. Dement. Sect. 7, 155-166.
10. Danysz, W., Parsons, C.G., Bresink, I., Quack, G., 1995a. Glutamate in CNS disorders. Drug News Perspect. 8, 261-277.
11. Danysz, W., Zajaczkowski, W., Parsons, C.G., 1995b. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6, 455-474.
12. B antagonists as potential therapeutic agents: previous hopes and present reality. Amino Acids 14, 235-239.
13. Ditzler, K., 1991. Efficacy and tolerability of memantine in patients with dementia syndrome. A double blind, placebo controlled trial. Arzneim.-Forsch. Drug Res. 41 (II), 773-780.
14. Eddy, N.B., Halbach, H., Isbell, H., Seevers, M.H., 1965. Drug dependence: its significance and characteristics. Bull. WHO 32, 721-733.
15. Glick, S.D., Rossman, K., Steindorf, S., Maisonneuve, I.M., Carlson, J.N., 1991. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195, 341-345.
16. Goudie, A.J., 1991. Animal models of drug abuse and dependence. In: Willner, P. (Ed.), Behavioural Models in Psychophramacology: Theoretical, Industrial and Clinical Perspectives. Cambridge University Press, Cambridge, pp. 453-484.
17. Hesselink, M., Smolders, H., Danysz, W., Lorenz, B., Eilbacher, B., de Boer, A.G., Breimer, D.D., 1997. Pharmacokinetic characterisation of two distinct classess on NMDA receptor antagonists using brain microdialysis. Soc. Neurosci. Abstr. 23, 921.
18. Higgins, G.A., Nguyen, P., Sellers, E.M., 1992. The NMDA antagonist dizocilpine (MK-801) attenuates motivational as well as somatic aspects of naloxone precipitated opioid withdrawal. Life Sci. 50, PL167-PL172.
19. Johnson, J.W., Ascher, P., 1987. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529.
20. Kolesnikov, Y.A., Maccecchini, M.-L., Pasternak, G.W., 1994. 1-Aminocyclopropanecarboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55 (18), 1393-1398.
21. Koyuncuoglu, H., Saydam, B., 1990. The treatment of heroin addicts with dextromethorphan. A double-blind comparison of dextromethorphan with chloropromazine. Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 147-152.
22. Kulagowski, J.J., 1996. Glycine-site NMDA receptor antagonists: an update. Expert Opin. Ther. Patents 6, 1069-1079.
23. Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T., Arakawa, M., Mishina, M., 1992. Molecular diversity of the NMDA receptor channel. Nature 358, 36-41.
24. Lutfy, K., Shen, K.Z., Kwon, I.S., Cai, S.X., Woodward, R.M., Keana, J.F.W., Weber, E., 1995. Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor glycine site antagonist. Eur. J. Pharmacol. 273, 187-189.
25. Mucha, R.F., Iversen, S.D., 1984. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology 82, 241-247.
26. Muir, K.W., Grosset, D.G., Gamzu, E., Lees, K.R., 1994. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br. J. Clin. Pharmacol. 38, 33-38.
27. Parsons, C.G., Gruner, R., Rozental, J., Millar, J., Lodge, D., 1993. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32, 1337-1350.
28. Parsons, C.G., Danysz, W., Quack, G., Hartmann, S., Lorenz, B., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Headley, P.M., Chizh, B., 1997. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioural characterization. J. Pharmacol. Exp. Ther. 283, 1264-1275.
29. Parsons, C.G., Danysz, W., Bartmann, A., Spielmanns, P., Frankiewicz, T., Hesselink, M., Eilbacher, B., Quack, G., 1998. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology (in press).
30. Popik, P., Skolnick, P., 1996. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53, 791-798.
31. Popik, P., Danysz, W., 1997. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by NMDA receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 280, 854-865.
32. Popik, P., Layer, R.T., Fossom, L., Benveniste, M., Getter-Douglas, B., Witkin, J.M., Skolnick, P., 1995. NMDA antagonist properties of the putative anti-addicitive drug, ibogaine. J. Pharmacol. Exp. Ther. 275, 753-760.
33. Priestley, T., Danks, P., Marshall, G.R., Kemp, J.A., Kulagowski, J.J., Leeson, P.D., Hill, R.G., 1994. L-701,324: a high affinity antagonist at the glycine-recognition site of the NMDA receptor. Br. J. Pharmacol. 113, 31P.
34. Robinson, T.E., Berridge, K.C., 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
35. Rogawski, M.A., 1993. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. 14, 325-331.
36. Saelens, J.K., Granat, F.R., Sawyer, W.K., 1971. The mouse jumping test: a simple screening method to estimate the physical dependence capacity of analgesics. Arch. Int. Pharmacodyn. Ther. 190, 213-218.
37. Troupin, A.S., Nendius, J.R., Cheng, F., Risinger, M.W., 1986. MK-801. In: Meldrum, B., Porter, R.J. (Eds.), New Anticonvul-sant Drugs. John Libbey, London, pp. 191-201.
38. Trujillo, K.A., Akil, H., 1991. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251, 85-87.
39. Tzschentke, T.M., Schmidt, W.J., 1995. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats. Neurosci. Lett. 193, 37-40.